Investigating the genetic causes of invasive mucinous adenocarcinoma of the lung
Patho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the Lung
This study is looking into the genes and pathways involved in a type of lung cancer called invasive mucinous adenocarcinoma, hoping to find new ways to diagnose and treat it better, so patients can have more effective options in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10836356 on NIH RePORTER |
What this research studies
This research focuses on understanding the genetic and molecular pathways that contribute to invasive mucinous adenocarcinoma (IMA) of the lung, a type of lung cancer that currently lacks effective treatment options. The team aims to identify specific genetic alterations and biomarkers that can help distinguish IMA from other similar cancers, which is crucial for accurate diagnosis and treatment. By exploring the HNF4A pathway and its downstream genes, the research seeks to uncover potential therapeutic targets for IMA. Patients may benefit from advancements in targeted therapies that arise from this investigation.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with invasive mucinous adenocarcinoma of the lung or those with suspected cases based on their cancer's histopathology.
Not a fit: Patients with other types of lung cancer or those whose cancers do not involve mucinous adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective therapies for invasive mucinous adenocarcinoma, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting genetic pathways in lung cancer, suggesting that this approach could yield significant advancements in treatment for invasive mucinous adenocarcinoma.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Maeda, Yutaka — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Maeda, Yutaka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.